首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 生技設備 > 2011年的核酸增幅市場主要指標(系列3)
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

2011年的核酸增幅市場主要指標(系列3)

2011 Nucleic Acid Amplification Dashboard Series 3

出版商 Percepta Associates Inc.
出版日期 2011年09月 商品編碼 203887
內容資訊 英文  
價格
US $ 3975 Company Wide PDF Price


2011年的核酸增幅市場主要指標(系列3) 是由出版商Percepta Associates Inc.在2011年09月所出版的。 這份英文市場調查報告書價格從美金3975起跳。

簡介

本報告以北美·歐洲科學家為對象所進行的調查內容,彙整出利用核酸增幅法的各種相關指標,核酸增幅整體市場及資級分類(Taq聚合脢的標準PCR・熱啟動Taq聚合脢・校正及聚合脢)的市場趨勢、彙整技術使用概況、技術滿意度、影響決策的要素等,為您概述為以下內容。

目錄

  • 摘要整理
  • 主要調査結果・分析
  • 核酸増幅介面
  • 核酸増幅的市場機會矩陣
  • 調查方法
  • 調查介紹
  • 受訪者的人口統計資料
  • 分子生物學的技術利用頻率
  • 核酸増幅技術利用頻率
  • 反應處理率/利用率・成長率
  • 受訪者回答的每次反應的費用
  • 整體市場規模・市場區隔規模・總體市場成長率
  • 市場佔有率:市場區隔別
  • 顧客滿意度・供應商改變的決策
  • 影響決策的產品功能
  • 一次・二次下游應用
  • 核酸増幅產品變更意願
  • 調查内容
  • 附錄

圖表

目錄

Abstract

image1

Description

Overview

Nucleic acid amplification is one of the most commonly performed molecular biology techniques and is a necessary precursor to a range of methods from gene cloning and site-directed mutagenesis to the quantitative analysis of gene expression. The Nucleic Acid Amplification Dashboard was developed from responses to a 21-question survey by 492 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the nucleic acid amplification market as a whole as well as for the following sub-segments:

  • Difficult PCR (e.g. GC rich, complex, long targets)
  • Digital PCR
  • Emulsion PCR
  • Fast PCR
  • High Fidelity PCR
  • High Resolution Melt (using real time PCR instrument)
  • Standard endpoint PCR
  • Standard endpoint RT-PCR
  • qPCR (real time PCR with genomic DNA template)
  • qRT-PCR (real time PCR with RNA or cDNA template)

While standard protocols may be well-defined, amplification markets are quite fluid, with significant influence from such external sources as:

  • An evolving intellectual property landscape
  • New pricing strategies from established suppliers
  • Application to emerging research areas such as gene silencing, SNP genotyping and rapid, whole genome sequencing

In order to dive more deeply into the characteristics and dynamics of the market for nucleic acid amplification products, Percepta has introduced the Nucleic Acid Amplification Dashboard, designed to take a snapshot of the current market landscape with the future goal of repeating and publishing the study to give Dashboard readers the ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

Survey Methodology

In July of 2011, Percepta fielded the Nucleic Acid Amplification Survey to a subset of the Percepta BioAnalytix"! Panel of life scientists. Individuals were invited by e-mail blast to click-through to a webpage at perceptabioanalytix.com where the survey was hosted. Invitations were delivered beginning on July 22, 2011 and results collected through August 3, 2011. A total of 492 scientists participated in the survey, of which 477 are actively engaged in performing nucleic acid amplification and 6 plan to use nucleic acid amplification methods in the next 12 months. Results based on the aggregate of collected responses are revealed in this Nucleic Acid Amplification Dashboard.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with 18.9% of respondents employed in an industry setting. 71.7% of respondents are from North America, while 26.7% reside in Europe.

Junior (Lab Technician, Graduate Student), mid-level (Post-Doctoral Fellow, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Professor/PI/Instructor (21.3% of respondents), Scientist/Senior Scientist (18.9% of respondents) and Post-Doctoral Fellow/Research Fellow (17.3% of respondents).

A wide variety of scientific areas of specialization is also evident, led by cell biology (named by 18.3% of respondents as their primary area of expertise), followed by biochemistry (15.9%) and microbiology/infectious disease/virology (12.0%).

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 55.3% of respondents work in labs where 1 to 5 people perform nucleic acid amplification experiments at least a few times each year; 37.6% in labs with 6 to 20 experimenters, and the remaining 7.1% in labs with greater than 20 bench scientists.

Table of Contents

  • Executive Summary
  • Key Findings and Implications
  • Nucleic Acid Amplification Dashboard
  • Nucleic Acid Amplification Market Opportunity Matrix
  • Survey Methodology
  • Survey Invitation Text
  • Respondent Demographics
  • Frequency of Performance of Life Science Techniques
  • Frequency of Performance of Nucleic Acid Amplification
  • Reaction Throughput and Market Growth Rates
  • Respondents' Stated Price per Reaction
  • Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • Market Shares by Segment (Share of Mentions)
  • Customer Satisfaction and Interest in Switching Suppliers
  • Product Features That Influence Purchasing Decisions
  • Primary and Secondary Downstream Applications
  • Desired Changes to Nucleic Acid Amplification Products
  • Survey Questionnaire
  • Appendix

Figures and Tables

  • Figure 1: Respondents' Place of Employment
  • Figure 2: Respondent' s Location
  • Figure 3: Respondents' Job Title
  • Figure 4: Respondents' Areas of Expertise/Specialization
  • Figure 5: Number of Employees in Respondents' Laboratories
  • Figure 6: Percentage of Respondents Performing Various Techniques at Least a Few Times per Year
  • Figure 7: Percentage of Respondents Performing Nucleic Acid Amplification
  • Figure 7A: Change in Percentage of Respondents Performing Nucleic Acid Amplification
  • Figure 8: Percentage of Respondents Performing Various Nucleic Acid Amplification Techniques at least a Few Times per Year
  • Figure 9: Percentage of Respondents Using Various Thermostable Polymerases for Nucleic Acid Amplification Techniques
  • Figure 10: Percentage of Respondents Performing Difficult PCR
  • Figure 11: Percentage of Respondents Performing Digital PCR
  • Figure 12: Percentage of Respondents Performing Emulsion PCR
  • Figure 13: Percentage of Respondents Performing Fast PCR
  • Figure 14: Percentage of Respondents Performing High Fidelity PCR
  • Figure 14A: Change in Percentage of Respondents Performing High Fidelity PCR
  • Figure 15: Percentage of Respondents Performing High Resolution Melt
  • Figure 16: Percentage of Respondents Performing Standard Endpoint PCR
  • Figure 17: Percentage of Respondents Performing Standard Endpoint RT-PCR
  • Figure 18: Percentage of Respondents Performing qPCR
  • Figure 19: Percentage of Respondents Performing qRT-PCR
  • Figure 20: Respondents' Primary Supplier for Difficult PCR
  • Figure 21: Respondents' Primary Supplier for Digital PCR
  • Figure 22: Respondents' Primary Supplier for Emulsion PCR
  • Figure 23: Respondents' Primary Supplier for Fast PCR
  • Figure 24: Respondents' Primary Supplier for High Fidelity PCR
  • Figure 24A: Change in Mention for Respondents' Primary Supplier for High Fidelity PCR
  • Figure 25: Respondents' Primary Supplier for High Resolution Melt
  • Figure 26: Respondents' Primary Supplier for Standard Endpoint PCR
  • Figure 27: Respondents' Primary Supplier for Standard Endpoint RT-PCR
  • Figure 28: Respondents' Primary Supplier for qPCR
  • Figure 29: Respondents' Primary Supplier for qRT-PCR
  • Figure 30: Respondents' Primary Supplier of Instruments for Standard PCR
  • Figure 30A: Change in Respondents' Primary Supplier of Instruments for Standard PCR
  • Figure 31: Respondents' Primary Supplier of Instruments for Real Time PCR
  • Figure 31A: Change in Respondents' Primary Supplier of Instruments for Real Time PCR
  • Figure 32: Respondents' Primary and Secondary Applications for End Products from Difficult PCR
  • Figure 33: Respondents' Primary and Secondary Applications for End Products from Digital PCR
  • Figure 34: Respondents' Primary and Secondary Applications for End Products from Emulsion PCR
  • Figure 35: Respondents' Primary and Secondary Applications for End Products from Fast PCR
  • Figure 36: Respondents' Primary and Secondary Applications for End Products from High Fidelity PCR
  • Figure 37: Respondents' Primary and Secondary Applications for End Products from High Resolution Melt
  • Figure 38: Respondents' Primary and Secondary Applications for End Products from Standard Endpoint PCR
  • Figure 39: Respondents' Primary and Secondary Applications for End Products from Standard Endpoint RT-PCR
  • Figure 40: Respondents' Primary and Secondary Applications for End Products from qPCR
  • Figure 41: Respondents' Primary and Secondary Applications for End Products from qRT-PCR
  • Figure 42: Non-current users of Nucleic Acid Amplification Products Future Plans

List of Tables

  • Table 1: Respondents' Area of Expertise (Values for Figure 4)
  • Table 2: Frequency of Performance of Various Life Science Techniques
  • Table 3: Frequency of Co-Performance of Various Life Science Techniques
  • Table 4: Percentage of Respondents Performing Nucleic Acid Amplification by Place of Employment and Location
  • Table 5: Frequency of Performance of Various Nucleic Acid Amplification Techniques
  • Table 6: Frequency of Co-Performance of Life Science Techniques with Nucleic Acid Amplification Techniques
  • Table 7: Frequency of Co-Performance of Nucleic Acid Amplification Techniques with Life Science Techniques
  • Table 8: Mean, Median and Trim Mean Monthly Throughput for Nucleic Acid Amplification Techniques
  • Table 8A: Change in Median Monthly Throughput for Nucleic Acid Amplification Methods - Comparison to the 2009 Dashboard
  • Table 8B: Mean, Median and Trim Mean Monthly Throughput for Nucleic Acid Amplification Methods by Organization Type
  • Table 9: Percentage of Respondents Performing Probe-based vs. DNA Binding-dye based Reactions for real time PCR
  • Table 10: Percentage of Respondents Performing Various Numbers of Amplification Reactions Per Month by Product Category
  • Table 11: Projected Growth in the Performance of Various Nucleic Acid Amplification Techniques
  • Table 12: Mean, Median and Trim Mean Price per Reaction for Nucleic Acid Amplification Techniques
  • Table 13: Change in Mean, Median and Trim Mean Price per Reaction for Nucleic Acid Amplification Techniques
  • Table 14: Estimated 2012 Global Market Size for Nucleic Acid Amplification Techniques
  • Table 15: Respondents' Primary Supplier for Difficult PCR by Market Segment
  • Table 16: Respondents' Primary Supplier for Digital PCR by Market Segment
  • Table 17: Respondents' Primary Supplier for Emulsion PCR by Market Segment
  • Table 18: Respondents' Primary Supplier for Fast PCR by Market Segment
  • Table 19: Respondents' Primary Supplier for High Fidelity PCR by Market Segment
  • Table 20: Respondents' Primary Supplier for High Resolution Melt by Market Segment
  • Table 21: Respondents' Primary Supplier for Standard Endpoint PCR by Market Segment
  • Table 22: Respondents' Primary Supplier for Standard Endpoint RT-PCR by Market Segment
  • Table 23: Respondents' Primary Supplier for qPCR by Market Segment
  • Table 24: Respondents' Primary Supplier for qRT-PCR by Market Segment
  • Table 25: Market Share Leaders for Nucleic Acid Amplification Products
  • Table 26: Respondents' Primary Supplier of Standard PCR Thermocyclers by Market Segment
  • Table 27: Respondents' Primary Supplier for Instruments for Real Time PCR by Market Segment
  • Table 28: Market Share Leaders for Standard and Real Time PCR Instruments
  • Table 29: Percentage of Respondents Satisfied with Various Nucleic Acid Amplification Techniques and Reasons for Dissatisfaction
  • Table 30: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • Table 31: Most Important Features of Nucleic Acid Amplification Products
  • Table 31A: Most Important Features of Nucleic Acid Amplification Products - Comparison to 2009 Nucleic Acid Amplification Dashboard
  • Table 32: Respondents' Primary and Secondary Applications for End Products from Difficult PCR (Values for Figure 32)
  • Table 33: Respondents' Primary and Secondary Applications for End Products from Digital PCR (Values for Figure 33)
  • Table 34: Respondents' Primary and Secondary Applications for End Products from Emulsion PCR (Values for Figure 34)
  • Table 35: Respondents' Primary and Secondary Applications for End Products from Fast PCR (Values for Figure 35)
  • Table 36: Respondents' Primary and Secondary Applications for End Products from High Fidelity PCR (Values for Figure 36)
  • Table 37: Respondents' Primary and Secondary Applications for End Products from High Resolution Melt (Values for Figure 37)
  • Table 38: Respondents' Primary and Secondary Applications for End Products from Standard Endpoint PCR (Values for Figure 38)
  • Table 39: Respondents' Primary and Secondary Applications for End Products from Standard Endpoint RT-PCR (Values for Figure 39)
  • Table 40: Respondents' Primary and Secondary Applications for End Products from qPCR (Values for Figure 40)
  • Table 41: Respondents' Primary and Secondary Applications for End Products from qRT-PCR (Values for Figure 41)
  • Table 42: Respondents' Primary Applications for End Products from Nucleic Acid Amplification

Press Release

2011年Bio-Rad在增幅試劑與即時PCR機器市場市占率成長

2011年10月17日

Global Information, Inc.已開始銷售Percepta Associates Inc.所發行的報告書「2011 Nucleic Acid Amplification Dashboard Series 3 (2011年的核酸增幅市場主要指標(系列3))」

由於預算變得嚴格,研究人員希望購買低價格的試劑。本報告書提供以淺顯易懂的格式、能比較2007年版和2009年版之是市場重要指標的市場規模、競爭市占率、成長率、顧客滿意度、終端用戶行動等數值。亦有助於增幅產品供應商繼續評估市場行銷策略的效果。市場包括以下區塊。

增幅試劑區塊

  • 增幅困難PCR (例如在GC利基上複雜的長目標)
  • 數位PCR
  • 乳膠 PCR
  • 高速PCR
  • 高忠實性PCR
  • 高解析度融解(即時PCR裝置使用)
  • 標準終端(end point)PCR
  • 標準終端(end point) RT-PCR
  • qPCR (使用RT-PCR和DNA模板)
  • qRT-PCR (RT- PCR和RNA或cDNA模板使用)

增幅機器區塊

  • 終端(end point)PCR
  • 即時PCR

依據增幅產品的終端用戶調查數據,許多的科學家對現在的產品不滿意,10種試劑區塊中,7種區塊45%以上基於性能和價格方面的理由,表達想變更到其他供應商的意向。Percepta的分析者Sarab Khandpur述說:「顧客希望有各式各樣的模板和兼容性佳的酵素,在極有限的預算中,尋求更低價的試劑。」。

Back to Top